Ragnar,
I probably should not make specific stock recommendations on
public message boards b/c I feel guilty and personally responsible when someone
follows my recommendation – and then the stock sells off!
Anyway, I believe the market over-reacted to GERN’s recent
announcement. In my view it contained more good news than bad. The most
important statement in that announcement in my view is the following: “Janssen has conducted an initial internal review of
efficacy, safety and pharmacokinetic data from a subset of patients from Part 1
of IMergeTM and this review indicated that emerging safety and efficacy in
IMergeTM is consistent with data reported from the pilot study conducted at
Mayo Clinic in MDS patients. IMergeTM will continue unmodified at this time.” I
find that quite encouraging.
In addition it’s not surprising
to me that there was an inadequate response to the 4.7 mg/kg dosage with regard to
the IMbark trial. One must remember that these people are extremely sick. People,
in fact, who have run out of options. People in many cases who do not have long to live. That is the reality. The lack of response at this very low dose is therefore not
surprising.
Below is a link to a pretty
good discussion w/regard to the recent announcement:
http://seekingalpha.com/news/3208146-geron-27-percent-premarket-uncertainties-imetelstat-studies
I’m still long the stock and have not sold any shares.